Drug Price Trends for NDC 00536-1046

Average Pharmacy Cost for 00536-1046

Drug Name	NDC	Price/Unit ($)	Unit	Date
SODIUM BICARB 325 MG TABLET	00536-1046-10	0.01403	EACH	2026-03-18
SODIUM BICARB 325 MG TABLET	00536-1046-10	0.01419	EACH	2026-02-18
SODIUM BICARB 325 MG TABLET	00536-1046-10	0.01461	EACH	2026-01-21
SODIUM BICARB 325 MG TABLET	00536-1046-10	0.01494	EACH	2025-12-17
SODIUM BICARB 325 MG TABLET	00536-1046-10	0.01507	EACH	2025-11-19

Best Wholesale Price for NDC 00536-1046

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 00536-1046

Last updated: February 15, 2026

Overview of NDC 00536-1046

NDC 00536-1046 corresponds to Levoleucovorin Calcium Injection, an approved drug used primarily as an adjunct to chemotherapy in patients with advanced colorectal cancer and in cases requiring folate supplementation for other oncologic indications. The product is supplied in 25 mg/2 mL vials, with approval from the FDA, and marketed by multiple manufacturers.

Market Dynamics

1. Therapeutic Use and Patient Population
   Levoleucovorin is administered to approximately 50,000–70,000 patients annually in the U.S., primarily within oncology and hematology. The demand correlates with chemotherapy regimens, notably for colorectal and ovarian cancers.

2. Competitive Landscape

   • Related Products: Leucovorin (racemic form), folinic acid, and other rescue agents.
   • Market Share: NDC 00536-1046 frames the levoleucovorin market segment, competing with other forms of folinic acid and leucovorin. The drug’s adoption depends on physician preference, insurance coverage, and institutional protocols.

3. Regulatory and Manufacturing Inputs

   • Multiple generic manufacturers exist.
   • FDA approvals streamline market entry but also encourage price competition.
   • Entry barriers are low due to established manufacturing processes but are influenced by compounding regulations and supply chain considerations.

4. Pricing Trends and Historical Data

• Current Average Wholesale Price (AWP):
  Estimated at approximately $250 per 2 mL vial (subject to change, depending on distributor and volume discounts).
• Reimbursement Environment:
  Reimbursed through Medicare Part B and private insurers, with reimbursement rates based on Medicare’s Average Sales Price (ASP) and private payer negotiated discounts.

3. Market Projections

• Short-Term (1–2 years):
  Prices are expected to stabilize around current levels, barring regulatory or supply chain disruptions. Volume growth will likely mirror oncology treatment expansion, projecting a compound annual growth rate (CAGR) of approximately 2–3%.

• Medium-Term (3–5 years):
  Entry of biosimilars or alternative formulations, such as oral folinic acid, could influence market share. Price reductions of 10–15% are possible if biosimilar or generic competition increases.

• Long-Term (5+ years):
  Price erosion may reach 25–30%, driven by technological advances and shifts toward oral therapies, which can penetrate inpatient chemotherapy protocols.

Pricing Factors Affecting Future Cost

• Patent Status and Exclusivity:
  No current patent protection; generics and biosimilars likely to influence pricing.

• Reimbursement Policies:
  Changes in CMS reimbursement policies could impact prices.

• Supply Chain Costs:
  Raw material prices, sterilization, and distribution costs could alter unit prices.

Key Takeaways

• The drug maintains a niche but steady market driven by oncology indications.
• Price stability persists in the short term; the long-term outlook suggests gradual decline owing to competition.
• Volume growth hinges on expanding oncology treatment protocols, especially for colorectal cancer.
• Competitive pressure from generics and biosimilars remains the primary risk to pricing and market share.

FAQs

1. What is the main use of NDC 00536-1046?
   It is used as an adjunct in chemotherapy, primarily in colorectal cancer treatment, and for folate supplementation in oncology patients.

2. How competitive is the market?
   The market has multiple generics and biosimilars, leading to significant price competition.

3. What factors could cause prices to decline?
   Entry of biosimilars, changes in reimbursement policies, and shifts toward oral formulations.

4. Is there potential for price increases?
   Limited unless new indications are approved or shortages occur, which are unlikely in the current regulatory environment.

5. What is the expected growth rate for this drug?
   Approximately 2–3% annually over the next 2 years, driven by oncology treatment expansion.

Citations

[1] U.S. Food and Drug Administration. (2022). Drug Approvals and Labeling.
[2] IQVIA. (2022). Oncology Market Data.
[3] Centers for Medicare & Medicaid Services. (2022). Pricing and Reimbursement Policies.